Compare
Align Technology Inc vs Edwards Lifesciences Corp vs Enovis Corp vs Zimmer Biomet Holdings, Inc.
| Latest fiscal year | Align Technology Inc ALGN | Edwards Lifesciences Corp EW | Enovis Corp ENOV | Zimmer Biomet Holdings, Inc. ZBH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.03B | $6.07B | $2.25B | $8.23B |
| Revenue growth (YoY) | +0.9% | +11.5% | +6.7% | +7.2% |
| Gross margin | 67.2% | 78.0% | 59.8% | n/a |
| Operating margin | 13.5% | 20.8% | -50.0% | 13.3% |
| Net margin | 10.2% | 17.6% | -52.7% | 8.6% |
| Net income | $410.35M | $1.07B | -$1.18B | $705.10M |
| EPS (Diluted) | $5.65 | $1.83 | -$20.75 | $3.55 |
| Operating cash flow | $593.22M | $1.60B | $217.29M | $1.70B |
| Free cash flow | $490.78M | $1.33B | $19.92M | $1.47B |
| Cash & equivalents | $1.09B | $2.94B | $36.39M | $591.90M |
| Total assets | $6.23B | $13.70B | $3.83B | $23.09B |
| Total liabilities | $2.18B | $3.36B | $2.34B | $10.39B |
| Shareholders' equity | $4.05B | $10.34B | $1.49B | $12.71B |
| Return on year-end equity | 10.1% | 10.3% | -79.5% | 5.5% |
| Shares outstanding | 71.36M | 580.70M | 57.19M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Align Technology Inc | Edwards Lifesciences Corp | Enovis Corp | Zimmer Biomet Holdings, Inc. |
|---|---|---|---|---|
| Latest | $4.03B Ended 2025-12-31 | $6.07B Ended 2025-12-31 | $2.25B Ended 2025-12-31 | $8.23B Ended 2025-12-31 |
| 1 year earlier | $4.00B Ended 2024-12-31 | $5.44B Ended 2024-12-31 | $2.11B Ended 2024-12-31 | $7.68B Ended 2024-12-31 |
| 2 years earlier | $3.86B Ended 2023-12-31 | $5.01B Ended 2023-12-31 | $1.71B Ended 2023-12-31 | $7.39B Ended 2023-12-31 |
| 3 years earlier | $3.73B Ended 2022-12-31 | $4.46B Ended 2022-12-31 | $1.56B Ended 2022-12-31 | $6.94B Ended 2022-12-31 |
| 4 years earlier | $3.95B Ended 2021-12-31 | $5.23B Ended 2021-12-31 | $1.43B Ended 2021-12-31 | $6.83B Ended 2021-12-31 |